Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Solid Tumors News

Page 32 - Solid Tumors News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

May 25, 2023
After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR /KEYNOTE-581 trial Final results will be presented at ASCO 2023... | May 25, 2023
New Zealand United States Thomas Hutson Corina Dutcus Gregory Lubiniecki Urologic Cancer Research
Source: marketscreener.com

SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting

May 25, 2023
- Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using Multiple Assessment Tools - - Substantial Reductions in MRI-Assessed Tumor Volume... | May 25, 2023
United States Samantha Hilson Sandler Jim Cassidy Fred Hutchinson Cancer Research Center European Organization For Research European Consensus Initiative
Source: marketscreener.com

Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

May 25, 2023
– Company Presents Poster on Overall Survival and Long-Term Safety Results from INTRIGUE Study; Second Poster Presents Analysis from INTRIGUE Patients without Detectable ctDNA at Baseline... | May 25, 2023
Hong Kong United States United Kingdom New Zealand West German Sebastian Bauer
Source: marketscreener.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

May 25, 2023
25.05.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating KEYTRUDA, ...
United States New Zealand Gregory Lubiniecki Corina Dutcus Thomas Hutson Global Clinical Development
Source: wallstreet-online.de

Tekla Capital Management LLC Acquires Shares of 283,281 Kura Oncology, Inc. (NASDAQ:KURA)

May 22, 2023
Tekla Capital Management LLC bought a new position in Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 283,281 shares of the company’s stock, valued at approximately $3,516,000. Tekla Capital Management LLC owned approximately 0.42% […]
Stifel Nicolaus Tekla Capital Management Dimensional Fund Advisors Raymond James Associates Metlife Investment Management Bridgefront Capital
Source: modernreaders.com

Wedbush Research Analysts Lower Earnings Estimates for Kura Oncology, Inc. (NASDAQ:KURA)

May 17, 2023
Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) – Equities researchers at Wedbush cut their Q2 2023 earnings per share estimates for shares of Kura Oncology in a report issued on Thursday, May 11th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.54) per share for the quarter, down from their prior estimate […]
Stifel Nicolaus Kura Oncology Inc Allspring Global Investments Holdings Nisa Investment Advisors Great West Life Assurance Co Denali Advisors
Source: theenterpriseleader.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science